UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TORULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Dated September 13, 2019
Commission FileNumber 001-36421
AURINIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
N/A
(Translation of Registrant’s Name)
#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250)708-4272
(Address and telephone number of registrant’s principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover ofForm 20-F orForm 40-F.
Form 20-F ☐ Form 40-F ☒
Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted byRegulation S-T Rule 101(b) (1): ☐
Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted byRegulation S-T Rule 101(b) (7): ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☒ No ☐
This Form6-K is hereby filed and incorporated by reference in the registrant’s Registration Statement on FormF-10 (FileNo. 333-222413).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: September 13, 2019
Aurinia Pharmaceuticals Inc. | ||||
By: | /s/ Dennis Bourgeault | |||
Name: | Dennis Bourgeault | |||
Title: | Chief Financial Officer |
2
EXHIBIT INDEX
Exhibit | Description of Exhibit | |
99.1 | Open Market Sale Agreement with Jefferies LLC dated September 13, 2019 | |
99.2 | Material Change report dated September 13, 2019 - ATM | |
99.3 | News Release - Aurinia Establishes At-the-Market Facility |
Exhibits 99.1 and 99.2 included with this report on Form6-K are hereby incorporated by reference as exhibits to the Registration Statement on FormF-10 of Aurinia Pharmaceuticals Inc. (FileNo. 333-222413), as amended or supplemented.
3